secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arch Therapeutics, Inc. (—)
CIK:        0001537561
Form:       8-K
Filed at:   2024-03-18T23:59:59+00:00
Accession:  0001437749-24-008311
Event type: debt
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arch Therapeutics closes $648K convertible note tranche, extends note maturity
------------------------------------------------------------------------------

- Fourth closing issued $648K aggregate principal (with $108K OID), warrants for 130,383 shares, and 9,779 inducement shares; net proceeds ~$450K.
- Notes amended: upon uplist, 95% of outstanding principal auto-converts at $0.50; maturity and uplist deadline extended to April 30, 2024.
- Fourth Notes bear 10% interest, convertible at $9.14, and have default premium of 125%.
- Fourth Warrants priced at $9.94, 5-year term, with beneficial ownership limitation of 4.99%-9.99%.
- Company intends proceeds for working capital; prior notes also amended (Amendments No. 15, 10, 1).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1537561/000143774924008311/0001437749-24-008311-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1537561/000143774924008311/arch20240315_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-008311

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer